Genmab A/S

DK

GMAB

Health Care

28.97 ₽

Current price

Hold
28.97 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    268 / 1361

  • Position in country

    108 / 253

  • Return on Assets, %

    13.2

    -40.3

  • Net income margin, %

    13.6

    -180

  • EBITDA margin, %

    35.6

    -168.2

  • Debt to Equity, %

    2.4

    3.2

  • Intangible assets and goodwill, %

    0.2

    0.2

  • Revenue CAGR 3Y, %

    17.6

    12.5

  • Total Equity change 1Y, %

    19.1

    -9

  • Revenue Y, % chg

    17.4

    0

  • P/E

    31

    31

  • P/BV

    4.2

    1.8

  • P/S

    8.2

    10.3

  • EV/S

    6.7

    7.5

  • EV/EBITDA

    20.7

    -1.6

  • Average Analyst recommendation

    Hold

    Hold

  • Average upside forecasts, %

    45.2

    131.1

  • Forward P/E

    24.3

    21.4

  • Expected dividend per share

    0

    0

  • Payout Ratio, %

    0

    0

Get an analytical review of this company

Competitors

Ranks

  • Bavarian Nordic A/S

    00%

  • Vertex Pharmaceuticals Inc

    00%

  • CSL Ltd

    00%

  • Regeneron Pharmaceuticals Inc

    00%

  • Gilead Sciences Inc

    00%

  • Genmab A/S

    00%

  • Ascendis Pharma A/S

    00%

  • Zealand Pharma A/S

    00%

  • Amgen Inc

    00%

  • AbbVie Inc

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    Denmark

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Biotechnology

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    19654.6

  • Ticker

    GMAB.OQ

  • ISIN

    US3723032062

  • IPO date

    2000-10-01

  • Availability on Russian exchanges

    No

  • Reporting for

    2024-02-14

  • Date fact. publication of reports

    2023-12-31

Company Description

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

A step towards better analytics

  • find the best promotions through the Screener
  • keep an eye on stock valuation
  • download detailed reports

and much more after free registration

Registration

More convenient from your phone? Download: